Acurx Pharmaceuticals (ACXP) to Release Quarterly Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXP) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Acurx Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ ACXP opened at $0.46 on Monday. The stock has a market capitalization of $9.04 million, a PE ratio of -0.42 and a beta of -1.71. The stock’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $1.29. Acurx Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $3.33.

Insider Buying and Selling

In other Acurx Pharmaceuticals news, CEO David P. Luci purchased 49,261 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was purchased at an average price of $1.01 per share, for a total transaction of $49,753.61. Following the purchase, the chief executive officer now directly owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This trade represents a 4.70 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 29.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research report on Friday, January 10th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.